GST cut on health insurance premium deferred, cancer drugs to become cheaper

New Delhi: The GST Council, headed by Finance Minister Nirmala Sitharaman, on Monday announced setting up a Group of Ministers (GoM) on slashing the tax rate on life and health insurance, as well as reducing the GST on cancer drugs and ‘namkeens’ (selected snacks). The GoM on life and health insurance will be headed by Bihar Deputy Chief Minister Samrat Choudhary, who is currently heading the panel on GST rate rationalisation.

The 54th GST Council meeting reached a “broad consensus” to bring relief to individuals and senior citizens with a decision on the GST applied to health insurance premiums. The current GST rate on health and life insurance policies stands at 18 per cent. Meanwhile, the GST Council announced to reduce the GST rate on cancer drugs to 5 per cent from 12 per cent and on namkeens to 12 per cent from 18 per cent. The members also agreed to form a GoM on compensation cess.

“The GST Council has agreed to form a GoM which will now take it up to study and decide on how to move forward on compensation of cess which will cease after March 2026,” said FM Sitharaman. The total cess collection projected until March 2026 stands at Rs 8.66 lakh crore. After settling the loan payments, a projected surplus of around Rs 40,000 crore is expected. Revenue Secretary Sanjay Malhotra said that the GST compensation cess may be discontinued post-debt repayments.

At a press conference after the meeting, Malhotra also said import of services by foreign airline companies will be exempt from GST. Universities and research centres established by central or state government laws, or those granted income tax exemptions, will now be exempt from paying GST on research funding, said FM Sitharaman. The GST panel also decided to introduce business-to-customer (B2C) GST invoicing.

This new system for GST invoice management will take effect from October 1. It was also announced to surge GST on car seats from 18 per cent to 28 per cent.

Related Posts

Pharma companies in a flux over Trump’s 200% tariff move on generics

India’s $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face tariffs of 100% from Aug…

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

New Delhi: A joint operation by the Delhi Police Crime Branch, the Central Drugs Standard Control Organisation (CDSCO) and the Gautam Buddha Nagar District Drug Department uncovered a suspected illegal…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

CDSCO declares 159 drug samples as NSQs in June

CDSCO declares 159 drug samples as NSQs in June